ATNM:NYE-Actinium Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.79

Change

+0.12 (+7.19)%

Market Cap

USD 0.05B

Volume

0.33M

Analyst Target

USD 70.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
TECH Bio-Techne Corp

+0.13 (+0.26%)

USD 8.03B
BHVN Biohaven Pharmaceutical Holdin..

-0.27 (-1.69%)

USD 1.64B
RCUS Arcus Biosciences Inc

+0.15 (+1.75%)

USD 0.91B
NUVB Nuvation Bio Inc

+0.04 (+1.77%)

USD 0.77B
DNA Ginkgo Bioworks Holdings

+0.16 (+2.02%)

USD 0.46B
CYBN Cybin Inc

+0.78 (+11.61%)

USD 0.15B
ADCT ADC Therapeutics SA

+0.45 (+23.81%)

USD 0.14B
PLX Protalix Biotherapeutics Inc

+0.01 (+0.60%)

USD 0.13B
OSTX OS Therapies Incorporated

-0.05 (-3.05%)

USD 0.07B
ANRO Alto Neuroscience, Inc.

+0.01 (+0.40%)

USD 0.07B

ETFs Containing ATNM

RJZ 0.00 % 0.75 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 42.06% 97% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.06% 97% N/A 97% N/A
Trailing 12 Months  
Capital Gain -81.53% 31% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.53% 31% F 1% F
Trailing 5 Years  
Capital Gain -67.22% 52% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -67.22% 52% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain 22.21% 73% C 86% B+
Dividend Return 22.21% 73% C 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 201.80% 30% F 4% F
Risk Adjusted Return 11.01% 68% D+ 30% F
Market Capitalization 0.05B 64% D 19% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.